DWTX Virios Therapeutics: Earnings per share for the trailing year

Public company logo of Virios Therapeutics (DWTX)

Dogwood Therapeutics, Inc. (DWTX) maintains a strong scientific reputation in fibromyalgia therapy, driving a trend that this GURU.Markets chart of trailing twelve-month (TTM) EPS dynamics captures at 96.50. While steady demand for antiviral agents supports the business, high development costs are leading to a rapid cash burn, creating significant liquidity pressure on the company.

DWTX Dogwood Therapeutics Inc. Earnings per share for the last twelve months (11/23/2025 - 11/19/2026)

DWTX (Virios Therapeutics): analytical breakdowns and indicator data

- market price and analyst price targets:
Fundamental company valuation:DWTX Dogwood Therapeutics, Inc.
Finished products of Dogwood Therapeutics Inc.

Dogwood Therapeutics, Inc. (DWTX) focuses on recruiting specialized virologists to develop therapies for neurological disorders. The annual percentage change in earnings per share (ttm) illustrates the effectiveness of this intellectual strategy. This metric compares current net income over twelve months with the same period last year, eliminating quarterly noise. Growth in this indicator confirms the capitalization of human resources, while a stable trend signals the resilience of the business model.